9,500 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Caption Management LLC

Caption Management LLC bought a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 9,500 shares of the biotechnology company's stock, valued at approximately $376,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its stake in shares of Veracyte by 49.7% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 237 shares during the last quarter. US Bancorp DE lifted its holdings in Veracyte by 57.4% during the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after buying an additional 647 shares during the period. Principal Securities Inc. grew its position in shares of Veracyte by 34.1% in the 4th quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after buying an additional 485 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Veracyte in the fourth quarter valued at about $91,000. Finally, Sterling Capital Management LLC raised its position in shares of Veracyte by 810.2% during the fourth quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 2,155 shares during the last quarter.

Veracyte Stock Performance

Veracyte stock traded down $1.84 during mid-day trading on Friday, reaching $29.37. The stock had a trading volume of 1,498,608 shares, compared to its average volume of 884,792. The firm has a market capitalization of $2.30 billion, a PE ratio of -195.80 and a beta of 2.14. Veracyte, Inc. has a fifty-two week low of $19.73 and a fifty-two week high of $47.32. The stock's 50-day simple moving average is $31.05 and its 200-day simple moving average is $37.12.

Veracyte (NASDAQ:VCYT - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The business had revenue of $118.63 million during the quarter, compared to the consensus estimate of $110.73 million. During the same quarter last year, the firm posted ($0.39) EPS. On average, research analysts forecast that Veracyte, Inc. will post 0.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VCYT has been the subject of a number of recent analyst reports. Stephens reissued an "overweight" rating and set a $45.00 target price on shares of Veracyte in a research report on Wednesday, March 26th. Guggenheim decreased their price objective on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Craig Hallum initiated coverage on shares of Veracyte in a report on Thursday, March 20th. They issued a "buy" rating and a $45.00 target price on the stock. Needham & Company LLC decreased their price target on Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a report on Thursday. Finally, StockNews.com lowered Veracyte from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Veracyte has a consensus rating of "Moderate Buy" and an average target price of $40.90.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.